(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 November 2009 (19.11.2009)

PCT

(10) International Publication Number
WO 2009/138707 A9

(51) **International Patent Classification**:
C07D 453/02 (2006.01) ***A61P 11/00*** (2006.01)
A61K 31/439 (2006.01)

(21) **International Application Number**:
PCT/GB2008/001647

(22) **International Filing Date**:
13 May 2008 (13.05.2008)

(25) **Filing Language**: English

(26) **Publication Language**: English

(71) **Applicants** *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE). **ARGENTA DISCOVERY LIMITED** [GB/GB]; 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR (GB).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **FORD, Rhonan, Lee** [GB/GB]; AstraZeneca, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **MATHER, Andrew, Nigel** [GB/GB]; AstraZeneca, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **METE, Antonio** [IT/GB]; AstraZeneca, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **BULL, Richard, James** [GB/GB]; Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR (GB). **SKIDMORE, Elizabeth, Anne** [GB/GB]; Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR (GB).

(74) **Agent**: **STANSFIELD, Kevin**; AstraZeneca AB, Global Intellectual Property, SE-151 85 Södertälje (SE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

(48) **Date of publication of this corrected version**:
28 January 2010

(15) **Information about Correction**:
see Notice of 28 January 2010

(54) **Title**: QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS



(I)

(57) **Abstract**: The invention provides named compounds of formula (I), wherein R4 is a N- sustituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for' the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.

WO 2009/138707 A9